Clinical Trials Browser

Phase 1 × Interventional × Carcinoma in Situ × Clear all

NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Phase 1 Completed

15 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06022029 2025-12-24

ON-5001

Phase 1 Recruiting

BreastDermatologicGenitourinaryGynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms

NCT05014139 2025-11-20

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Terminated

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT05085977 2025-01-27

ADVANCED-1

Phase 1 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05085990 2025-01-27

ADVANCED-1

Phase 1 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT02698293 2022-11-22

PDT Plus Vitamin D3 for Anal Dysplasia

Phase 1 Withdrawn

Carcinoma in Situ

NCT04109092 2020-12-14

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Phase 1 Withdrawn

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT03106610 2018-05-24

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

Phase 1 Terminated

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT00410865 2011-12-07

Wild Type p53 Adenovirus for Oral Premalignancies

Phase 1 Terminated

Carcinoma in Situ, Mouth Neoplasms

NCT00109655 2008-10-03

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

Phase 1 Unknown

Non-Muscle Invasive Bladder Neoplasms, Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell